Table 1

Patients' clinical features

CaseAge at diagnosis, y/sexStage at diagnosisLymphocyte count, ×109/L
Stage at studyMedication intakeHepatitis B or CYears (from diagnosis to study)
At diagnosisHighestAt study
64/F A0 9.8 17.6 1.39 A0 Ramipril, nitroglycerin skin patches, phenytoin (since 2005), anticholesterol drug Negative 13 
51/F A0 11.6 31.3 2.1 A0 Atorvastatin, antihypertensive, aspirin Negative 21 
50/M A2 16.2 16.2 3.16 A0 Antihypertensive/alcohol Negative 19 
63/M A0 10.6 13.6 3.5 A0 Bisoprolol, pantoprazole, perindopril, ticlopidine, simvastatin, pentoxifylline Negative 13 
73/F A2 15.7 15.7 3.86 A0 None NA 
53/F A0 27.6 31.0 4.0 A0 Losartan, hydrochlorothiazide NA 29 
53/F A0 11.7 12.9 2.5 A0 Carvedilol, ramipril, aspirin, atorvastatin, omega-3 fatty acids, acarbose, insulin NA 21 
41/F A0 12.3 26.0 1.4 A0 Hormonal replacement NA 16 
66/M A0 8.7 14.6 4.0 A0 Antihypertensive, aspirin Negative 13 
CaseAge at diagnosis, y/sexStage at diagnosisLymphocyte count, ×109/L
Stage at studyMedication intakeHepatitis B or CYears (from diagnosis to study)
At diagnosisHighestAt study
64/F A0 9.8 17.6 1.39 A0 Ramipril, nitroglycerin skin patches, phenytoin (since 2005), anticholesterol drug Negative 13 
51/F A0 11.6 31.3 2.1 A0 Atorvastatin, antihypertensive, aspirin Negative 21 
50/M A2 16.2 16.2 3.16 A0 Antihypertensive/alcohol Negative 19 
63/M A0 10.6 13.6 3.5 A0 Bisoprolol, pantoprazole, perindopril, ticlopidine, simvastatin, pentoxifylline Negative 13 
73/F A2 15.7 15.7 3.86 A0 None NA 
53/F A0 27.6 31.0 4.0 A0 Losartan, hydrochlorothiazide NA 29 
53/F A0 11.7 12.9 2.5 A0 Carvedilol, ramipril, aspirin, atorvastatin, omega-3 fatty acids, acarbose, insulin NA 21 
41/F A0 12.3 26.0 1.4 A0 Hormonal replacement NA 16 
66/M A0 8.7 14.6 4.0 A0 Antihypertensive, aspirin Negative 13 

NA indicates not available.

Close Modal

or Create an Account

Close Modal
Close Modal